Our top pick for
Zai Lab Limited is a biotechnology business based in the US. Zai Lab shares (ZLAB) are listed on the NASDAQ and all prices are listed in US Dollars. Zai Lab employs 1,194 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$100.75|
|52-week range||$80.46 - $193.54|
|50-day moving average||$120.74|
|200-day moving average||$148.17|
|Wall St. target price||$212.07|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-6.23|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||-1.23%|
|1 month (2021-09-24)||-15.94%|
|3 months (2021-07-23)||-32.83%|
|6 months (2021-04-23)||-41.79%|
|1 year (2020-10-23)||15.54%|
|2 years (2019-10-23)||238.20%|
|3 years (2018-10-23)||553.80%|
|5 years (2016-10-20)||N/A|
|Revenue TTM||$86.8 million|
|Gross profit TTM||$32.2 million|
|Return on assets TTM||-29.12%|
|Return on equity TTM||-50.21%|
|Market capitalisation||$9.8 billion|
TTM: trailing 12 months
There are currently 3.1 million Zai Lab shares held short by investors – that's known as Zai Lab's "short interest". This figure is 21% up from 2.5 million last month.
There are a few different ways that this level of interest in shorting Zai Lab shares can be evaluated.
Zai Lab's "short interest ratio" (SIR) is the quantity of Zai Lab shares currently shorted divided by the average quantity of Zai Lab shares traded daily (recently around 585699.61685824). Zai Lab's SIR currently stands at 5.22. In other words for every 100,000 Zai Lab shares traded daily on the market, roughly 5220 shares are currently held short.
However Zai Lab's short interest can also be evaluated against the total number of Zai Lab shares, or, against the total number of tradable Zai Lab shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Zai Lab's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Zai Lab shares in existence, roughly 30 shares are currently held short) or 0.0396% of the tradable shares (for every 100,000 tradable Zai Lab shares, roughly 40 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Zai Lab.
Find out more about how you can short Zai Lab stock.
We're not expecting Zai Lab to pay a dividend over the next 12 months.
Over the last 12 months, Zai Lab's shares have ranged in value from as little as $80.46 up to $193.54. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Zai Lab's is 1.2401. This would suggest that Zai Lab's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, and infectious diseases primarily in Greater China. The company's commercial products include Zejula for the treatment of breast cancer and non-small cell lung cancer; Optune, a device that delivers tumor treating fields; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other lymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; TPX-0022, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin-17; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. It has development, license, and collaboration agreements with GlaxoSmithKline; Paratek Bermuda, Ltd. ; Five Prime Therapeutics, Inc. ; Entasis Therapeutics Holdings, Inc.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.